论文部分内容阅读
目的探讨及评价NP方案与TP方案在晚期非小细胞肺癌(NSCLC)治疗中的疗效及不良反应。方法对54例经病理证实的晚期NSCLC的临床资料进行回顾性分析。比较两组化疗方案在局部晚期NSCLC的近期疗效、不良反应和1、2年的生存率。结果 NP和TP两组化疗方案的有效率分别为62.5%(10/16)和68.42%(26/38),1年生存率分别为50.2%和52.3%,2年生存率分别为15.2%和18.1%,两组疗效无显著差异。不良反应主要为Ⅲ～IV级骨髓抑制、Ⅰ～Ⅱ级的胃肠道反应和合并感染,经支持对症治疗均能缓解。TP方案合并肺部真菌感染的机会增加。结论 NP方案与TP方案在晚期非小细胞肺癌(NSCLC)治疗中有相对较好疗效,近期疗效及不良反应相似无显著性差异,从经济卫生性价比来看NP方案更适合于基层晚期非小细胞肺癌患者。
Objective To investigate and evaluate the efficacy and adverse reactions of NP regimen and TP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods The clinical data of 54 patients with pathologically confirmed advanced NSCLC were analyzed retrospectively. The short-term effects, adverse reactions and 1 and 2-year survival rates of two chemotherapy regimens in locally advanced NSCLC were compared. Results The effective rates of chemotherapy regimen in NP and TP groups were 62.5% (10/16) and 68.42% (26/38), respectively. The 1-year survival rates were 50.2% and 52.3%, respectively, and the 2-year survival rates were 15.2% and 18.1%, no significant difference between the two groups. Adverse reactions were mainly grade Ⅲ ~ IV myelosuppression, Ⅰ ~ Ⅱ grade gastrointestinal reactions and co-infection, symptomatic treatment can support the relief. TP regimen with increased risk of pulmonary fungal infection. Conclusion NP and TP regimens in the treatment of advanced non-small cell lung cancer (NSCLC) have a relatively good effect, the short-term efficacy and adverse reactions similar to no significant difference from the perspective of cost-effective economy and NP program is more suitable for the late basal non-small cell Lung cancer patients.